Dr Hal Barron
Chief Scientific Officer and President, R&D
Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He is a member of the Board and the Corporate Executive Team.
His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Hal was previously a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc.
He is Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company.
Hal holds a Bachelor of Science degree in Physics from Washington University in St. Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.
He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.
Find out more
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Discover our latest financial performance announcement and search for historical quarterly results materials
Board of Directors
The Board of Directors is responsible for the group's system of corporate governance and is ultimately accountable for the group's activities, strategy, risk management and financial performance.
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business